论文部分内容阅读
目的探讨含左氧氟沙星的三联疗法作为一线方案对幽门螺杆菌感染治疗的有效性和安全性。方法选择2010年6月-2012年3月105例确诊为幽门螺杆菌感染的初治患者,随机分为兰索拉唑肠溶胶囊+左氧氟沙星+阿莫西林(A组)和兰索拉唑肠溶胶囊+克拉霉索+阿莫西林组(B组),经治疗7d后比较两组根除率和不良反应发生率。结果 A组,B组幽门螺杆菌符合方案分析根除率分别为90.5%,74.4%,意向性治疗根除率分别为85.4%,70.0%,A组根除率高于B组,差异有统计学意义(P<0.05)。A组,B组不良反应发生率分别为3.6%,2.0%差异无统计学意义(P>0.05)。结论以左氧氟沙星、阿莫西林、兰索拉唑肠溶胶囊的三联疗法能显著提高幽门螺杆菌感染的初治成功率,不良反应少,安全有效。
Objective To investigate the efficacy and safety of triple therapy with levofloxacin as a first-line treatment for Helicobacter pylori infection. Methods From June 2010 to March 2012, 105 newly diagnosed Helicobacter pylori infection patients were randomly divided into Lansoprazole enteric-coated capsules + levofloxacin + amoxicillin (group A) and lansoprazole Soluble capsule + clarithromycin + amoxicillin group (B group). After 7 days of treatment, the eradication rate and incidence of adverse reactions in both groups were compared. Results The eradication rates of Helicobacter pylori in group A and group B were 90.5% and 74.4%, respectively. The eradication rates of intent-to-treat were 85.4% and 70.0%, respectively. The eradication rate of group A was higher than that of group B, the difference was statistically significant P <0.05). The incidences of adverse reactions in group A and group B were 3.6% and 2.0%, respectively, with no significant difference (P> 0.05). Conclusion Triple therapy with levofloxacin, amoxicillin and lansoprazole enteric-coated capsules can significantly improve the success rate of initial treatment of Helicobacter pylori infection with fewer adverse reactions and is safe and effective.